Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth significantly in U87MGde2-7 glioblastoma multiforme (GBM) models and A431 squamous xenograft models of Nu/Nu mice[1].
Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth and pEGFR levels in EGFRvIII-positive GBM SN0199 PDX models of NSG mice[1].
Depatuxizumab (2-40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth with dose dependent manner in SCC15 xenograft models of SCID Beige mice[1].
| Animal Model: | U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice[1] |
| Dosage: | 10, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth significantly more than Cetuximab (HY-P9905).
Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364).
|
| Animal Model: | EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice[1] |
| Dosage: | 10, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth significantly and reduced levels of pEGFR.
|
| Animal Model: | A431 squamous xenograft model of Nu/Nu mice[1] |
| Dosage: | 10, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg.
Inhibited tumor growth by 58% at 40 mg/kg.
|
| Animal Model: | SCC15 xenograft model of SCID Beige mice[1] |
| Dosage: | 2, 10, 20, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth with dose manner.
Reduced the level of pEGFR and total EGFR in time-dependent.
Reduced cell proliferation as measured by phospho-histone H3.
Increased apoptosis as measured by caspase-3 cleavage.
Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg.
|
